Related Experiment Video
Updated: Mar 7, 2026

08:40
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
Published on: August 1, 2013
18.8K
Immune modulation by dendritic-cell-based cancer vaccines
Chaitanya Kumar1, Sakshi Kohli, Poonamalle Parthasarathy Bapsy
1APAC Biotech Pvt Ltd, Gurgaon, India, chaitanya@apacbiotech.com.
Journal of Biosciences
|February 24, 2017
Summary
Cancer immunotherapy harnesses the immune system to fight tumors. This review focuses on dendritic cell (DC)-based vaccines, exploring their potential and combination therapies for enhanced anti-cancer immunity.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- The interaction between host immunity and tumor cells offers novel therapeutic strategies.
- Cancer immunotherapy aims to modulate the immune system to eliminate cancer cells.
- This involves targeting the tumor microenvironment or enhancing immune cell activity against tumors.
Purpose of the Study:
- To review current cancer immunotherapy approaches.
- To specifically highlight dendritic cell (DC)-based cancer vaccines.
- To discuss DC-based vaccines in clinical trials for various cancers.
Main Methods:
- Literature review of immunotherapy strategies.
- Focus on dendritic cell (DC) vaccine development and clinical applications.
- Analysis of immune system components and pathways involved in anti-tumor immunity.
Main Results:
- Dendritic cell (DC)-based vaccines are a key area of cancer immunotherapy research.
- Several DC-based vaccines are currently undergoing clinical trials for different cancer types.
- Tumor immunity is complex, involving multiple immune components and pathways.
Conclusions:
- Cancer immunotherapy, particularly DC-based vaccines, shows promise in cancer treatment.
- Combination therapies (chemotherapy, radiation, immunotherapy) may offer synergistic benefits.
- Further research into optimizing DC vaccines and combination strategies is warranted.
More Related Videos
Related Concept Videos
Cancer Vaccines
1.2K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K
Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Cell-mediated Immune Responses
85.4K
Overview
85.4K
Cytotoxic T Cells-mediated Immune Response
7.7K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.7K
T Cell Activation and Clonal Selection
16.8K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
16.8K
Vaccinations
52.8K
Overview
52.8K

